Affordable Access

deepdyve-link
Publisher Website

Benefits of Metformin in Attenuating the Hallmarks of Aging

Authors
  • Kulkarni, Ameya S1, 2
  • Gubbi, Sriram3
  • Barzilai, Nir1, 2
  • 1 Institute for Aging Research, Albert Einstein College of Medicine, Bronx, New York
  • 2 Department of Medicine, Division of Endocrinology, Albert Einstein College of Medicine, Bronx, New York
  • 3 Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
Type
Published Article
Journal
Cell metabolism
Publication Date
Apr 24, 2020
Volume
32
Issue
1
Pages
15–30
Identifiers
DOI: 10.1016/j.cmet.2020.04.001
PMID: 32333835
PMCID: PMC7347426
Source
PubMed Central
License
Unknown

Abstract

Metformin is the first drug to be tested for its age-targeting effects in a large clinical trial. In this Perspective, Kulkarni et al. review how metformin acts on its primary and secondary targets to attenuate the hallmarks of aging, highlighting its utility as an effective gerotherapeutic intervention.

Report this publication

Statistics

Seen <100 times